GSK Q3 2019 results

GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)

Issued: London, UK

Download the Q3 2019 results announcement: 3 2019 results announcement PDF - 938.9KB

Financial highlights

  • Reported Group sales £9.4 billion +16% AER, +11% CER (Pro-forma growth +6% CER*); Pharmaceuticals £4.5 billion +7% AER, +3% CER; Vaccines £2.3 billion +20% AER, +15% CER; Consumer Healthcare
    £2.5 billion +30% AER, +25% CER (Pro-forma growth +3% CER*)
  • Total Group operating margin 22.9%; Adjusted Group operating margin 29.7% reflecting increased spending on R&D and priority assets, and the impact of generic Advair in the US, partly offset by Vaccines performance (Pharmaceuticals 24.1%; Vaccines 50.3%; Consumer Healthcare 24.3%)
  • Total EPS 31.4p +9% AER, -1% CER, Adjusted EPS 38.6p +9% AER, +1% CER reflecting operating performance and lower effective tax rate offset by increased profit allocation to non-controlling interests
  • 9 months net cash flow from operations £4.6 billion. Free cash flow £2.5 billion
  • 19p dividend declared for the quarter, continue to expect 80p for FY19
  • Consumer Healthcare JV with Pfizer completed 31 July creating new world leader in Consumer Healthcare
  • 2019 Adjusted EPS guidance improved to expectation of around flat at CER from a decline of -3% to -5%

Product and pipeline highlights

  • Shingrix sales £535 million +87% AER, +76% CER driven by continuing strong execution in the US
  • Total Respiratory sales £806 million +25% AER, +19% CER. Nucala £203 million +40% AER, +33% CER
    Trelegy £139 million +>100% AER, +>100% CER
  • Total HIV sales £1.3 billion, +5% AER, flat at CER. Two-drug regimen sales £119 million
  • Continued progress to strengthen and advance R&D pipeline including:

Oncology:

  • Positive data presented at ESMO from PRIMA trial of Zejula monotherapy showing significant improvement in PFS in women with ovarian cancer regardless of biomarker status. On track to file by end 2019
  • Positive headline data from pivotal DREAMM-2 study of belantamab mafodotin (GSK2857916) for multiple myeloma. On track to file by end 2019
  • Positive data from GARNET study of dostarlimab for advanced or recurrent endometrial cancer. On track to file by end 2019
  • Positive data presented at ESMO on GSK3359609 (ICOS receptor agonist) plus pembrolizumab in head and neck squamous cell carcinoma. Phase II/III registrational trial announced

Respiratory:

  • Nucala approved in EU for self-administration by patients with severe eosinophilic asthma
  • Trelegy Ellipta submitted to the FDA for use in patients with asthma

HIV:

  • Long-acting injectable cabotegravir + rilpivirine submitted to EMA as the first monthly treatment for HIV
  • Positive phase III results from ATLAS-2M study of cabotegravir + rilpivirine administered every 8 weeks

Other:

  • Phase III start for first-in-class antibiotic, gepotidacin, in uncomplicated urinary tract infection and urogenital gonorrhoea
  • Daprodustat filed in Japan for patients with renal anaemia due to chronic kidney disease

Emma Walmsley, Chief Executive Officer, GSK said:

“GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance.  This quarter we have continued to strengthen our pipeline and have advanced assets in Respiratory, HIV and, notably, Oncology, where we are on track to file three innovative medicines by year end, following positive pivotal trial data.  We also achieved a significant milestone with the completion of our new Consumer Healthcare Joint Venture with Pfizer, to create a new world leading consumer healthcare business.”

About GSK

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com/about-us

Assumptions and cautionary statement regarding forward-looking statements

The Group’s management believes that the assumptions outlined above are reasonable, and that the aspirational targets described in this report are achievable based on those assumptions. However, given the longer term nature of these expectations and targets, they are subject to greater uncertainty, including potential material impacts if the above assumptions are not realised, and other material impacts related to foreign exchange fluctuations, macro-economic activity, changes in regulation, government actions or intellectual property protection, actions by our competitors, and other risks inherent to the industries in which we operate.

This webpage contains statements that are, or may be deemed to be, “forward-looking statements”. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those on this webpage, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk Factors’ in the Group’s Annual Report on Form 20-F for 2018. Any forward looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this report.